Tech Company Financing Transactions

Tizona Therapeutics Funding Round

Abingworth, Canaan Partners and Amgen Ventures invested in a $43 million Series B funding round for Tizona Therapeutics. The round was announced on 3/8/2016.

Transaction Overview

Company Name
Tizona Therapeutics
Announced On
3/8/2016
Transaction Type
Venture Equity
Amount
$43,000,000
Round
Series B
Investors

Abingworth (Lead Investor) (Shelley Chu)

Canaan Partners (Lead Investor) (Nina Kjellson)

Amgen Ventures

Astellas Venture Capital

InterWest Partners (Arnie Oronsky)

Lightstone Ventures (Jean George)

MPM Capital

Proceeds Purpose
Proceeds will be used to advance the company's immunotherapy programs. We expect Tizona's anti-CCR4 antibody to play an important role in inducing antitumor activity by depleting regulatory T cells (Tregs), a type of cell crucial to establishing and maintaining an immunosuppressive tumor microenvironment. In addition to the anti-CCR4 antibody program, proceeds from the financing will be used to advance Tizona's pipeline, including the company's IL-35 programs. IL-35 is a recently discovered immunosuppressive cytokine, predominantly expressed by Tregs.

Company Information

Company Status
Private & Independent
Industry
Biopharmaceutical
Mailing Address
4000 Shoreline Ct. 200
South San Francisco, CA 94080
USA
Phone
Undisclosed
Website
www.tizonatx.com
Email Address
[email protected]
Overview
Tizona Therapeutics, Inc. is a preclinical stage biotechnology company that is developing multiple, innovative immuno-oncology therapies.
Profile
Tizona Therapeutics LinkedIn Company Profile
Social Media
Tizona Therapeutics Company Twitter Account
Company News
Tizona Therapeutics News
Facebook
Tizona Therapeutics on Facebook
YouTube
Tizona Therapeutics on YouTube

Management Team

Title
Name
Email & Social
Chairman
Luke Evnin
  Luke Evnin LinkedIn Profile  Luke Evnin Twitter Account  Luke Evnin News  Luke Evnin on Facebook
Vice President
Courtney Beers
  Courtney Beers LinkedIn Profile  Courtney Beers Twitter Account  Courtney Beers News  Courtney Beers on Facebook
Vice President
John Corbin
  John Corbin LinkedIn Profile  John Corbin Twitter Account  John Corbin News  John Corbin on Facebook
VP - Bus. Development
Svetlana Lucas
  Svetlana Lucas LinkedIn Profile  Svetlana Lucas Twitter Account  Svetlana Lucas News  Svetlana Lucas on Facebook
VP - Operations
Christine O'Brien
  Christine O'Brien LinkedIn Profile  Christine O'Brien Twitter Account  Christine O'Brien News  Christine O'Brien on Facebook

 

 

Browse more venture capital transactions:

Prev: 3/8/2016: Zaloni venture capital transaction
Next: 3/8/2016: Shinesty venture capital transaction

 

Share this article

 

About Database of VC Transactions

Our team works diligently to report on all VC transactions involving tech companies. VC investment data records reported here come from news reports and company announcements. The data comes to us via our partnership with VentureDeal.com, an affiliated venture.

 

Additional Resources for Entrepreneurs

Lists of Venture Capital and Private Equity Firms

Franchise Opportunities

Contributors

Business Glossary

 

Copyright © 2001-2024. Gaebler Ventures. All rights reserved.